| http://purl.uniprot.org/citations/32707001 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/32707001 | http://www.w3.org/2000/01/rdf-schema#comment | "MicroRNA (miRNA) inhibition is a promising therapeutic strategy in several disease indications. MRG-110 is a locked nucleic acid-based antisense oligonucleotide that targets miR-92a-3p and experimentally was shown to have documented therapeutic effects on cardiovascular disease and wound healing. To gain first insights into the activity of anti-miR-92a in humans, we investigated miR-92a-3p expression in several blood compartments and assessed the effect of MRG-110 on target derepression. Healthy adults were randomly assigned (5:2) to receive a single intravenous dose of MRG-110 or placebo in one of seven sequential ascending intravenous dose cohorts ranging from 0.01 to 1.5 mg/kg body weight. MiR-92a-3p whole blood levels were time and dose dependently decreased with half-maximal inhibition of 0.27 and 0.31 mg/kg at 24 and 72 h after dosing, respectively. In the high-dose groups, >95% inhibition was detected at 24-72 h postinfusion and significant inhibition was observed for 2 weeks. Similar inhibitory effects were detected in isolated CD31+ cells, and miR-92a-3p expression was also inhibited in extracellular vesicles in the high-dose group. Target derepression was measured in whole blood and showed that ITGA5 and CD93 were increased at a dose of 1.5 mg/kg. Single-cell RNA sequencing of peripheral blood cells revealed a cell type-specific derepression of miR-92a targets. Together this study demonstrates that systemic infusion of anti-miR-92a efficiently inhibits miR-92a in the peripheral blood compartment and derepresses miR-92a targets in humans."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.org/dc/terms/identifier | "doi:10.1089/nat.2020.0871"xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Fischer A."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Fougerousse F."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Montgomery R."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Dimmeler S."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Zeiher A.M."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "John D."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Allee G."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Paty I."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Abplanalp W.T."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Darville H."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Gosgnach W."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/author | "Pestano L."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/date | "2020"xsd:gYear |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/name | "Nucleic Acid Ther"xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/pages | "335-345"xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/title | "Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study."xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://purl.uniprot.org/core/volume | "30"xsd:string |
| http://purl.uniprot.org/citations/32707001 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/32707001 |
| http://purl.uniprot.org/citations/32707001 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/32707001 |
| http://purl.uniprot.org/uniprot/#_A8K6A5-mappedCitation-32707001 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/32707001 |
| http://purl.uniprot.org/uniprot/#_B4E3F4-mappedCitation-32707001 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/32707001 |
| http://purl.uniprot.org/uniprot/#_B2R627-mappedCitation-32707001 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/32707001 |